CATEGORY: METABOLIC & BLOOD SUGAR
Adults with type 2 diabetes who were randomly assigned to bariatric surgery kept their blood sugar meaningfully lower than those assigned medicines and lifestyle care for as long as twelve years, in a pooled follow-up of four U.S. randomized trials published in JAMA. At seven years, the surgery group’s HbA1c had dropped 1.6 percentage points from a baseline of 8.7%, versus a 0.2-point drop in the medical group—and 18.2% of surgery patients were in diabetes remission, compared with 6.2% of those treated with medicines and lifestyle alone.1
Four Small Trials Joined Into One Long View
Individually, randomized trials of bariatric surgery—operations that change the digestive system to treat obesity and related disease—have been limited in size and follow-up, which is exactly the gap the researchers set out to close. The ARMMS-T2D project pooled four single-center U.S. trials run between 2007 and 2013, like four small streams joined into one river that can be followed farther downstream. Each trial had assigned adults with type 2 diabetes and obesity, by chance, to either surgery (gastric bypass, sleeve gastrectomy or adjustable banding) or medical and lifestyle management. Of 305 eligible participants, 262 enrolled in the long-term follow-up and were tracked for a median of 11 years—the longest randomized comparison of the two approaches to date, though a modest group for detecting rare outcomes.
A Point and a Half of Blood Sugar, and What Remission Meant
HbA1c is a blood test reflecting average blood sugar over about three months; participants started the trials with poorly controlled diabetes, averaging 8.2% to 8.7%. The between-group difference—1.4 percentage points at seven years, still 1.1 points at twelve—came despite the surgery group using fewer diabetes medications throughout. Remission, defined as blood sugar back in the healthy range without any diabetes medication, told the starkest story: 18.2% of the surgery group versus 6.2% of the medical group at seven years, and 12.7% versus none at all at twelve. One caveat the researchers report plainly: during follow-up, 25% of the people originally assigned to medical care eventually chose surgery, and everyone was analyzed in their original group—a standard approach that, if anything, shrinks the measured difference.
The Other Side of the Ledger
Surgery’s advantage came with costs. Anemia (low red blood cell counts), bone fractures and stomach or intestinal complaints were all more common in the surgery group—consequences consistent with how these operations change digestion and nutrient absorption. Four participants died during the long years of follow-up, two in each group, and major heart events did not differ—though with 262 people, the study was too small to settle questions about rare outcomes. Surgery remains a major medical decision with tradeoffs of its own, and candidacy depends on individual health circumstances that specialists evaluate case by case.
A Race Run Before the Newest Medicines Arrived
These trials began between 2007 and 2013, before today’s most effective weight-loss and diabetes drugs existed. A medical-management group treated now, with modern medications available, might close some of the gap—the study cannot say. What it can say is something no shorter trial could: the metabolic benefits of surgery were still visible more than a decade later, not as a temporary dip but as a durable difference in the course of the disease.
Key Takeaways
- Across four pooled randomized trials, bariatric surgery produced larger and longer-lasting blood sugar improvements than medicines and lifestyle care—a 1.4-percentage-point HbA1c advantage at seven years, still 1.1 points at twelve—while using fewer diabetes medications.
- Diabetes remission at seven years occurred in 18.2% after surgery versus 6.2% with medical care; at twelve years, 12.7% versus none.
- Surgery carried higher rates of anemia, fractures and digestive side effects, and it remains a major decision with individual tradeoffs.
- The trials predate the newest weight-loss and diabetes drugs, so the comparison reflects the medical care of the early 2010s.
References
- Courcoulas AP, Patti ME, Hu B, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA. 2024;331(8):654–664. link